Clinical characteristics and outcomes of BRCA-associated ovarian cancer: Genotype and survival

Cancer Genetics

Volumn 205, Issue 1-2, 2012, Pages 34-41

  Liu, Joyce ^a   Cristea, Mihaela C ^b   Frankel, Paul ^c   Neuhausen, Susan L ^d   Steele, Linda ^d   Engelstaedter, Verena ^a   Matulonis, Ursula ^a   Sand, Sharon ^e   Tung, Nadine ^f   Garber, Judy E ^a   Weitzel, Jeffrey N ^b,e  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b City of Hope ^*  (United States)

^c Division of Information Sciences   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e Division of Clinical Cancer Genetics   (United States)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

BRCA1; BRCA2; Cancer; Genetics; Ovarian carcinoma

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; EPITHELIUM TUMOR; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; CYSTADENOCARCINOMA, SEROUS; FEMALE; FOLLOW-UP STUDIES; GENES, BRCA1; GENES, BRCA2; GENOTYPE; HETEROZYGOTE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84860230447     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2012.01.008     Document Type: Article

References (41)

1. Risch H.A., McLaughlin J.R., Cole D.E.C., et al. Prevalence and Penetrance of Germline BRCA1 and BRCA2 Mutations in a Population Series of 649 Women with Ovarian Cancer. Am J Hum Genet 2001, 68:700-710.
2. Moslehi R., Chu W., Karlan B., et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 2000, 66:1259-1272.
3. Robles-Diaz L., Goldfrank D.J., Kauff N.D., et al. Hereditary ovarian cancer in Ashkenazi Jews. Fam Cancer 2004, 3:259-264.
4. Antoniou A., Pharoah P.D., Narod S., et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003, 72:1117-1130.
5. Pharoah P.D.P., Easton D.F., Stockton D.L., et al. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. Cancer Res 1999, 59:868-871.
6. Johannsson O.T., Ranstam J., Borg A., et al. Survival of BRCA1 Breast and Ovarian Cancer Patients: A Population-Based Study from Southern Sweden. J Clin Oncol 1998, 16:397-404.
7. Rubin S.C., Ivor B., Kian B., et al. Clinical and Pathological Features of Ovarian Cancer in Women with Germ-Line Mutations of BRCA1. N Engl J Med 1996, 335:1413-1416.
8. Aida H., Takakuwa K., Nagata H., et al. Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1. Clin Cancer Res 1998, 4:235-240.
9. Boyd J., Sonoda Y., Federici M.G., et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000, 283:2260-2265.
10. Ben David Y., Chetrit A., Hirsh-Yechezkel G., et al. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol 2002, 20:463-466.
11. Cass I., Baldwin R.L., Varkey T., et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003, 97:2187-2195.
12. Majdak E.J., Debniak J., Milczek T., et al. Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma. Cancer 2005, 104:1004-1012.
13. Chetrit A., Hirsh-Yechezkel G., Ben-David Y., et al. Effect of BRCA1/2 Mutations on Long-Term Survival of Patients With Invasive Ovarian Cancer: The National Israeli Study of Ovarian Cancer. J Clin Oncol 2008, 26:20-25.
14. Tan D.S.P., Rothermundt C., Thomas K., et al. "BRCAness" Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated With BRCA1 and BRCA2 Mutations. J Clin Oncol 2008, 26:5530-5536.
15. Vencken P.M., Kriege M., Hoogwerf D., et al. Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann Oncol 2011, 22:1346-1352.
16. Foulkes W.D., Metcalfe K., Sun P., et al. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 2004, 10:2029-2034.
17. Ramus S.J., Fishman A., Pharoah P.D., et al. Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations. Eur J Surg Oncol 2001, 27:278-281.
18. Pal T., Permuth-Wey J., Kapoor R., et al. Improved survival in BRCA2 carriers with ovarian cancer. Fam Cancer 2007, 6:113-119.
19. Fong P.C., Boss D.S., Yap T.A., et al. Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers. N Engl J Med 2009, 361:123-134.
20. Fong P.C., Yap T.A., Boss D.S., et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010, 28:2512-2519.
21. Tutt A., Robson M., Garber J.E., et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235-244.
22. Audeh M.W., Carmichael J., Penson R.T., et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010, 376:245-251.
23. Narod S.A., Foulkes W.D. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004, 4:665-676.
24. O'Donovan P.J., Livingston D.M. BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis 2010, 31:961-967.
25. Quinn J.E., Carser J.E., James C.R., et al. BRCA1 and implications for response to chemotherapy in ovarian cancer. Gynecol Oncol 2009, 113:134-142.
26. Sandhu S.K., Wenham R.M., Wilding G., et al. First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers. ASCO Meeting Abstracts 2010, Vol. 28:3001.
27. Gelmon K.A., Hirte H.W., Robidoux A., et al. Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer. ASCO Meeting Abstracts 2010, Vol. 28:3002.
28. Edwards S.L., Brough R., Lord C.J., et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008, 451:1111-1115.
29. Sakai W., Swisher E.M., Karlan B.Y., et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008, 451:1116-1120.
30. Swisher E.M., Sakai W., Karlan B.Y., et al. Secondary BRCA1 Mutations in BRCA1-Mutated Ovarian Carcinomas with Platinum Resistance. Cancer Res 2008, 68:2581-2586.
31. Sakai W., Swisher E.M., Jacquemont C., et al. Functional Restoration of BRCA2 Protein by Secondary BRCA2 Mutations in BRCA2-Mutated Ovarian Carcinoma. Cancer Res 2009, 69:6381-6386.
32. Bunting S.F., Callén E., Wong N., et al. 53BP1 Inhibits Homologous Recombination in BRCA1-Deficient Cells by Blocking Resection of DNA Breaks. Cell 2010, 141:243-254.
33. Bouwman P., Aly A., Escandell J.M., et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol 2010, 17:688-695.
34. Turner N., Tutt A., Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004, 4:814-819.
35. Bast R.C., Mills G.B. Personalizing Therapy for Ovarian Cancer: BRCAness and Beyond. J Clin Oncol 2010, 28:3545-3548.
36. Veeck J., Ropero S., Setien F., et al. BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. J Clin Oncol 2010, 28:e563-e564. author reply e565-e566.
37. Brown L.A., Irving J., Parker R., et al. Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Gynecol Oncol 2006, 100:264-270.
38. Konstantinopoulos P.A., Spentzos D., Karlan B.Y., et al. Gene Expression Profile of BRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer. J Clin Oncol 2010, 28:3555-3561.
39. Bolton K. BRCA2 Mutations Associated with Improved Survival for Ovarian Cancer. Presented at: American Association for Cancer Research 102nd Annual Meeting; April 2-6, 2011; Orlando, FL. [Abstract 2752].
40. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615. Cancer Genome Atlas Research Network.
41. Yang D., Khan S., Sun Y., et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011, 306:1557-1565.